Senescent Cells: A Therapeutic Target in Cardiovascular Diseases

卷:12

Review

关键词: SMOOTH-MUSCLE-CELLS;    ENDOTHELIAL PROGENITOR CELLS;    PROTEIN-A DEFICIENCY;    DNA-DAMAGE RESPONSE;    CARDIAC STEM-CELL;    SECRETORY PHENOTYPE;    PREMATURE SENESCENCE;    NITRIC-OXIDE;    ATRIAL-FIBRILLATION;    HEART-FAILURE;   

DOI  :  10.3390/cells12091296

来源: SCIE

【 摘 要 】

Senescent cell accumulation has been observed in age-associated diseases including cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence-associated secretory phenotype (SASP) factors that may cause or worsen many cardiovascular diseases. Therapies targeting senescent cells, especially senolytic drugs that selectively induce senescent cell removal, have been shown to delay, prevent, alleviate, or treat multiple age-associated diseases in preclinical models. Some senolytic clinical trials have already been completed or are underway for a number of diseases and geriatric syndromes. Understanding how cellular senescence affects the various cell types in the cardiovascular system, such as endothelial cells, vascular smooth muscle cells, fibroblasts, immune cells, progenitor cells, and cardiomyocytes, is important to facilitate translation of senotherapeutics into clinical interventions. This review highlights: (1) the characteristics of senescent cells and their involvement in cardiovascular diseases, focusing on the aforementioned cardiovascular cell types, (2) evidence about senolytic drugs and other senotherapeutics, and (3) the future path and clinical potential of senotherapeutics for cardiovascular diseases.